Orchid Pharma's Alathur API facility successfully completes USFDA inspection

The Alathur facility specializes in the production of Cephalosporin antibiotics

CAHO and Orchid Pharma partnership kicks off with conference on antimicrobial resistance

This strategic alliance is aimed at strengthening hospital systems and developing advanced AMR interventions

Orchid Pharma Q2 FY25 PAT up 26% YoY driven by strategic initiatives for market expansion

Orchid Pharma launches Rs. 500 Cr QIP programme

With this QIP placement, the Dhanuka group, which took over the company in 2018, is also meeting its mandatory obligation to dilute 15 percent stake in the company by March 2023

Orchid Pharma updates on PLI scheme benefits for its subsidiary

The approval has been accorded by IFCI Limited for manufacturing of the product "7 ACA"

Orchid Pharma to transfer IKKT undertaking to JV with Bionpharma

The turnover of its NPNC Formulations Division (IKKT Undertaking) for FY 2020-2021 is Rs.21.33 Cr

Orchid Pharma develops new molecule OCID-5090

Allecra Therapeutics would now either directly or through out license file for NDA of this molecule.